Search

Your search keyword '"Nitta, Janet"' showing total 18 results
Start Over Author "Nitta, Janet"
18 results on '"Nitta, Janet"'

9. Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.

Author

Speziali, Craig, Daly, Andrew, Abuhaleeqa, Mohamed, Nitta, Janet, Abou Mourad, Yasser, Seftel, Matthew D., and Paulson, Kristjan

Subjects
LYMPHOBLASTIC leukemia, CELL transplantation, ACUTE leukemia, BUSULFAN, TOTAL body irradiation
Abstract

The optimal conditioning regimen for adults undergoing transplantation for acute lymphoblastic leukemia (ALL) remains undetermined. Cyclophosphamide and total body irradiation (Cy/TBI) has emerged as a standard myeloablative regimen but is associated with significant toxicity. We compared outcomes between patients undergoing transplant for ALL at centers using Cy/TBI as standard of care and another center using fludarabine, busulfan, and low-dose TBI (400 cGy) in combination with anti-thymocyte globulin as its standard. Among 146 patients (74 Cy/TBI and 72 Flu/Bu/TBI) there were no significant differences in overall or progression-free survival between groups. Non-relapse mortality was similar (12% vs. 16.7% for Cy/TBI and Flu/Bu/TBI, respectively, p =.62) despite the Flu/Bu/TBI group having significantly worse performance status. Flu/Bu/TBI resulted in significantly lower cumulative incidence of relapse compared with Cy/TBI (2-year point estimate 18.5% vs. 31.5%, p =.05). These results demonstrate similar outcomes for patients receiving Flu/Bu/TBI versus Cy/TBI. Flu/Bu/TBI may allow the possibility of providing myeloablative conditioning to patients with poor performance status. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

11. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)

Author

Venner, Christopher P., primary, Connors, Joseph M., additional, Sutherland, Heather J., additional, Shepherd, John D., additional, Hamata, Linda, additional, Mourad, Yasser Abou, additional, Barnett, Michael J., additional, Broady, Raewyn, additional, Forrest, Donna L., additional, Hogge, Donna E., additional, Nantel, Stephen H., additional, Narayanan, Sujaatha, additional, Nevill, Thomas J., additional, Nitta, Janet, additional, Power, Maryse M., additional, Toze, Cynthia L., additional, Smith, Clayton A., additional, and Song, Kevin W., additional

Published
2010
Full Text
View/download PDF

12. Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning

Author

Kanda, Junya, primary, Rizzieri, David A., additional, Gasparetto, Cristina, additional, Long, Gwynn D., additional, Chute, John P., additional, Sullivan, Keith M., additional, Morris, Ashley, additional, Smith, Clayton A., additional, Hogge, Donna E., additional, Nitta, Janet, additional, Song, Kevin, additional, Niedzwiecki, Donna, additional, Chao, Nelson J., additional, and Horwitz, Mitchell E., additional

Published
2010
Full Text
View/download PDF

13. The Use of Novel Agents In Patients with Multiple Myeloma Initially Treated with Allogeneic Stem Cell Transplantation Results In A Significant Prolongation of Post Relapse Survival.

Author

Venner, Christopher P., primary, Sutherland, Heather, additional, Shepherd, John, additional, Mourad, Yasser Abou, additional, Barnett, Michael J., additional, Forrest, Donna L., additional, Hogge, Donna E., additional, Nantel, Stephen H., additional, Narayanan, Sujaatha, additional, Nevill, Thomas J., additional, Nitta, Janet, additional, Power, Maryse, additional, Toze, Cynthia, additional, Smith, Clayton, additional, and Song, Kevin, additional

Published
2010
Full Text
View/download PDF

15. Exposure to Novel Agents Increases Post Relapse Survival in Patients with High Risk Myeloma Defined by Early Relapse (<12 months).

Author

Venner, Christopher P., primary, Connors, Joseph M., additional, Sutherland, Heather J., additional, Shepherd, John D., additional, Hamata, Linda, additional, Mourad, Yasser Abou, additional, Barnett, Michael J, additional, Forrest, Donna L., additional, Hogge, Donna E., additional, Nantel, Stephen H., additional, Narayanan, Sujaatha, additional, Nevill, Thomas J., additional, Nitta, Janet, additional, Power, Maryse M, additional, Toze, Cynthia L., additional, Smith, Clayton, additional, and Song, Kevin, additional

Published
2009
Full Text
View/download PDF

16. Induction Therapy with High-Dose Dex Alone in Newly Diagnosed Myeloma Patients Produces a 57% Partial Response and Is Predictive of Progression Free Survival.

Author

Irvine, David A., primary, Barnett, Michael J., additional, Brinkman, Ryan, additional, Forrest, Donna L., additional, Hogge, Donna E., additional, Lavoie, Julye, additional, Lei, Linda, additional, Nantel, Stephen H., additional, Nevill, Thomas J., additional, Nitta, Janet, additional, Shepherd, John, additional, Song, Kevin, additional, Toze, Cynthia, additional, and Sutherland, Heather, additional

Published
2006
Full Text
View/download PDF

17. Daclizumab Therapy Improves Outcome in Steroid Refractory Acute Graft Versus Host Disease (aGVHD).

Author

Doocey, Richard T., primary, Greenwood, Matthew J., additional, Warkentin, Dawn, additional, Song, Kevin W., additional, Le, Alan, additional, Nitta, Janet, additional, Nevill, Thomas J., additional, Barnett, Michael J., additional, Forrest, Donna L., additional, Hogge, Donna E., additional, Lavoie, Julye C., additional, Nantel, Stephen H., additional, Shepherd, John D., additional, Sutherland, Heather J., additional, Toze, Cynthia L., additional, and Smith, Clayton A., additional

Published
2004
Full Text
View/download PDF

18. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).

Author

Venner, Christopher P., Connors, Joseph M., Sutherland, Heather J., Shepherd, John D., Hamata, Linda, Mourad, Yasser Abou, Barnett, Michael J., Broady, Raewyn, Forrest, Donna L., Hogge, Donna E., Nantel, Stephen H., Narayanan, Sujaatha, Nevill, Thomas J., Nitta, Janet, Power, Maryse M., Toze, Cynthia L., Smith, Clayton A., and Song, Kevin W.

Subjects
MULTIPLE myeloma, STEM cell transplantation, THALIDOMIDE, MEDICAL protocols, DRUG therapy, COMBINATION drug therapy, PATIENTS
Abstract

The treatment of multiple myeloma (MM) has changed with the advent of thalidomide, bortezomib, and lenalidomide, the so-called novel agents (NAs). Given the complexity of MM therapy in the NA era we pursued a population based study to assess for improvements in survival as well as to characterize the relevance of early relapse (within 12 months) and the International Staging System in this clinical setting. We reviewed our experience with 460 patients with MM treated with autologous stem cell transplant (ASCT) between 1988 and 2008, of whom 306 had relapsed. The cohort was divided into two groups based upon relapse pre-2004 and relapse during/after 2004 (2004+), which correlated to availability of bortezomib and lenalidomide. Improvements in both overall survival (OS) (median 32.0 months vs. 71.8 months; p < 0.001) and post-relapse survival (PRS) (median 15.2 months vs. 42.8 months; p < 0.001) correlated with the NA era. Exposure to NAs conferred a better PRS (median 35.7 months vs. 9.1 months; p < 0.001). Although all patients had improvements in survival, those who relapsed late continued to do better. Lastly, in the NA era, the ISS remains an important prognostic tool in relapse, but only in the late relapsing cohort. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results